-
-
On Feb. 15, 2011, a 30-month-old U.S.-born child of Somali descent developed a skin rash 14 days after returning from a trip to Kenya and 1 day after visiting a child care center.
-
Basically, people now feel nothing is safe to eat. They don't know what choices to make.
-
The April 14 issue of the New England Journal of Medicine contains two articles on boceprevir, a new designer molecule that has demonstrated a dramatic improvement in outcomes for patients with genotype 1 hepatitis C.
-
ZOSTAVAX®, which had previously received FDA approval for prevention of herpes zoster (HZ) and post-herpetic neuralgia in individuals 60 years of age and older, had its approval extended to include people 50-59 years of age on March 24, 2011.
-
A retrospective study was conducted of 563 children who presented over the last decade to two pediatric immunodeficiency centers in the United Kingdom.
-
GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18] Vaccine, Recombinant) previously received FDA approval for prevention of cervical, vulvar, and vaginal cancer and associated precancerous lesions, and for prevention of genital warts in males and females 9-26 years of age.
-
In a prospective observational study, investigators of the HIV-CAUSAL Collaboration evaluated data from participating HIV clinics in Europe and the U.S. Veterans Administration system to determine the optimal CD4+ T cell count at which combination antiretroviral therapy (cART) should be initiated.
-
Coccidioidal infections are always unique the travel history often provides the right clue for the practitioner but first you have to think to ask the right question.
-
Emerging multidrug resistant gram negative bacteria are spreading across the health care continuum, becoming entrenched in non-acute and long term care settings and threatening vulnerable hospital patients with untreatable infections, epidemiologists reported recently in Dallas at the annual conference of the Society for Healthcare Epidemiology of America (SHEA).
